Epstein-Barr virus and nasopharyngeal carcinoma

Chinese Journal of Cancer

Volumn 33, Issue 12, 2014, Pages 581-590

  Young, Lawrence S ^a   Dawson, Christopher W ^b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

EBV; Gastric carcinoma; Latency; Nasopharyngeal carcinoma

Indexed keywords

B CELL LYMPHOMA; B LYMPHOCYTE; COMPLICATION; EPITHELIUM CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; NASOPHARYNX TUMOR; STOMACH TUMOR; VIROLOGY;

B-LYMPHOCYTES; EPITHELIAL CELLS; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, B-CELL; NASOPHARYNGEAL NEOPLASMS; STOMACH NEOPLASMS;

EID: 84909967044     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10197     Document Type: Review

References (99)

1. [1] de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol, 2012,13:607-615.
2. [2] Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004,4:757-768.
3. [3] Tao Q, Young LS, Woodman CB, et al. Epstein-Barr virus (EBV) and its associated human cancers—genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci, 2006,11:2672-2713.
4. [4] Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol, 2001,1:75-82.
5. [5] Rickinson AB, Kieff E. Epstein-Barr Virus. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams and Wilkins, 2001:2575-2627.
6. [6] Old LJ, Boyse EA, Oettgen E, et al. Precipitating antibody in human serum to an antigen prersent in cultured Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A, 1966,56:1699-1704.
7. [7] de Schryver A, Friberg S, Klein G, et al. Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin Exp Immunol, 1969,5:443-459.
8. [8] zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopses of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature, 1970,228:1056-1058.
9. [9] Henle W, Henle G, Ho HC, et al. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst, 1970,44:225-231.
10. [10] Henle W, Ho JH, Henle G, et al. Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int J Cancer, 1977,20:663-672.
11. [11] Wolf H, zur Hausen H, Becker V. EB-viral genomes in epitelial nasopharyngeal carcinoma cells. Nature New Biol, 1973,244:245-247.
12. [12] Zeng Y, Zhang LG, Wu YC, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Brr vírus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer, 1985,36:545-547.
13. [13] Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell, 1986,47:883-889.
14. [14] Pathmanathan R, Prasad U, Chandrika G, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus neoplasia. Am J Pathol, 1995,146:1355-1367.
15. [15] Wei K, Xu Y, Liu J, et al. Histopathological classification of nasopharyngeal carcinoma. Asian Pacific J Cancer Prev, 2011,12:1141-1147.
16. [16] Ji X, Zhang W, Xie C, et al. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer, 2011,129:724-732.
17. [17] Shibata D, Tokunaga M, Uemura Y, et al. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma. Am J Pathol, 1991,139:469-474.
18. [18] Fujii T, Kawai T, Saito K, et al. EBER-1 expression in thymic carcinoma. Acta Pathol Jpn, 1993,43:107-110.
19. [19] Raab-Traub N, Rajadurai P, Flynn K, et al. Epstein-Barr virus infection in carcinoma of the salivary gland. J Virol, 1991,65:7032-7036.
20. [20] Weinberg E, Hoisington S, Eastman AY, et al. Uterine cervical lymphoepithelial-like carcinoma. Absence of Epstein-Barr virus genomes. Am J Clin Pathol, 1993,99:195-199.
21. [21] Dadmanesh F, Peterse JL, Sapino A, et al. Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology, 2001,38:54-61.
22. [22] Kelly G, Bell A, Rickinson AB. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA1. Nat Med, 2002,8:1098-1104.
23. [23] Brooks L, Yao QY, Rickinson AB, et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol, 1992,66:2689-2697.
24. [24] Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin‘s disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med, 1993,177: 339-349.
25. [25] Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet, 1991,337:320-322.
26. [26] Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol, 1988,69:1051-1065.
27. [27] Speck SH, Strominger JL. Transcription of Epstein-Barr virus in latently infected, growth-transformed lymphocytes. In: Klein G, ed. Advances in viral oncology. New York: Raven Press, 1989:133-150.
28. [28] Moody CA, Scott RS, Su T, et al. Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence. J Virol, 2003,77:8555-8561.
29. [29] Tempera I, Klichinsky M, Lieberman PM. EBV latency types adopt alternative chromatin conformations. PLoS Pathog, 2011,7:e1002180.
30. [30] Chen H, Lee JM, Zong Y, et al. Linkage between STAT regulation and Epstein-Barr virus gene expression. J Virol, 2001,75:2929-2937.
31. [31] Frappier L. Role of EBNA1 in NPC tumourigenesis. Sem Cancer Biol, 2012,22:154-161.
32. [32] Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalised lymphocytes transforms established rodent cells. Cell, 1985,43:831-840.
33. [33] Dawson CW, Port RJ, Young LS. The role of EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma. Sem Cancer Biol, 2012,22:144-153.
34. [34] Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell, 1995,80:389-399.
35. [35] Pathmanathan R, Prasad U, Sadler R, et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med, 1995, 333:693-698.
36. [36] Khabir A, Karray H, Rodriguez S, et al. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in North African nasopharyngeal carcinomas. Virol J, 2005,2:39.
37. [37] Fruehling S, Longnecker R. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMPA2 is essential for blocking BCR-mediated signal transduction. J Virol, 1997,235:241-251.
38. [38] Miller CL, Burkhardt AL, Lee JH, et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity, 1995,2:155-166.
39. [39] Caldwell RG, Wilson JB, Anderson SJ, et al. Epstein-Barr virus LMP2A drives B-cell development and survival in the absence of normal B cell receptor signals. Immunity, 1998,405-411.
40. [40] Scholle F, Bendt KM, Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol, 2000,74:10681-10689.
41. [41] Morrison JA, Raab-Traub N. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of beta-catenin signaling. J Virol, 2005,79:2375-2382.
42. [42] Fukuda M, Longnecker R. Epstein-Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras/PI3-K/Akt pathway. J Virol, 2007,81:9299-9306.
43. [43] Allen MD, Young LS, Dawson CW. The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol, 2005,79:1789-1802.
44. [44] Lu J, Lin WH, Chen SY, et al. Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem, 2006,281:8806-8814.
45. [45] Kong QL, Hu LJ, Cao JY, et al. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog, 2010, 6:e1000940.
46. [46] Shah KM, Stewart SE, Wei W, et al. The EBV-encoded latent membrane proteins, LMP2A and LMP2B, limit the actions of interferon by targeting interferon receptors for degradation. Oncogene, 2009,28:3903-3914.
47. [47] Stewart S, Dawson CW, Takada K, et al. Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci U S A, 2004,101:15730-15735.
48. [48] Busson P, McCoy R, Sadler R, et al. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol, 1992,66:3257-3262.
49. [49] Heussinger N, Büttner M, Ott G, et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol, 2004,203:696-699.
50. [50] Paramita DK, Fatmawati C, Juwana H, et al. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls. J Med Virol, 2011,4:665-678.
51. [51] Takada K. Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Sem Cancer Biol, 2012,22:162-165.
52. [52] Samanta M, Iwakiri D, Kanda T, et al. EB virus-encoded RNAs are recognised by RIG-1 and activate signalling to induce type I IFN. EMBO J, 2006,25:4207-4214.
53. [53] Iwakiri D, Sheen TS, Chen JY, et al. Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene, 2005, 24:1767-1773.
54. [54] Hitt MM, Allday MJ, Hara T, et al. EBV gene expression in an NPC-related tumour. EMBO J, 1989,8:2639-2651.
55. [55] Marquitz AR, Raab-Traub N. The role of miRNAs and EBV BARTS in NPC. Sem Cancer Biol, 2012,22:166-172.
56. [56] Pfeffer S, Zavolan M, Grasser FA, et al. Identification of virus-encoded microRNAs. Science, 2004,304:734-736.
57. [57] Lo AKF, Dawson CW, Jin DY, et al. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J Pathol, 2012,227:392-403.
58. [58] Wong AM, Kong KL, Tsang JW, et al. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer, 2012,118:698-710.
59. [59] Chan JY, Gao W, Ho WK, et al. Overexpression of Epstein-Barr virus-encoded microRNA-BART7 in undifferentiated naso-pharyngeal carcinoma. Anticancer Res, 2012,32:3201-3210.
60. [60] Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A, 2010,107:6328-6333.
61. [61] Meckes DG, Shair KHY, Marquitz AR, et al. Human tumor virus utilizes exosomes for intercellular communication. Proc Natl Acad Sci U S A, 2010,107:20370-20375.
62. [62] Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, et al. Expression of BARF1 gene encoded by Epstein-Barr virus in naso-pharyngeal carcinoma biopsies. Cancer Res, 2000,60;5584-5588.
63. [63] zur Hausen A, Brink AA, Craanen ME, et al. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adeno-carcinomas: expression of the transforming BARF1 gene. Cancer Res, 2000,60: 2745-2748.
64. [64] Shim AHR, Chang RA, Chen X, et al. Multipronged attenuation of macrophage-colony stimulating factor signaling by Epstein-Barr virus BARF1. Proc Natl Acad Sci U S A, 2012,109:12962-12967.
65. [65] Sheng W, Decaussin G, Sumner S, et al. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene, 2001,20:1176-1185.
66. [66] Seto E, Ooka T, Middeldorp J, et al. Reconstruction of naso-pharyngeal carcinoma-type infection induced tumorigenicity. Cancer Res, 2008,68:1030-1036.
67. [67] Houali K, Wang X, Shimizu Y, et al. A new diagnostic marker for secreted Epstein-Barr virus-encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with naso-pharyngeal carcinoma. Clin Cancer Res, 2007,13:4493-5000.
68. [68] Tzellos S, Farrell PJ. Epstein-Barr virus sequence variation—biology and disease. Pathogens, 2012,1:156-74.
69. [69] Sample J, Young L, Martin B, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol, 1990,64:4084-4092.
70. [70] Rickinson AB, Young LS, Rowe M. Influence of the Epstein-Barr vírus nuclear antigen EBNA2 on the growth phenotype of virus-transformed B cells. J Virol, 1987, 61:1310-1317.
71. [71] Khanim F, Yao QY, Niedobitek G, et al. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-asssociated tumors from different geographic locations. Blood, 1996,88:3491-3501.
72. [72] Tierney RJ, Edwards RH, Sitki-Green, D, et al. Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis, 2006,193:287-297.
73. [73] Midgley RS, Blake NW, Yao QY, et al. Novel intertypic recombinants of Epstein-Barr virus in the Chinese population. J Virol, 2000,74:1544-1548.
74. [74] Liu P, Fang X, Feng Z, et al. Direct sequencing and characterization of a clinical isolate of Epstein-Barr virus from nasopharyngeal carcinoma tissue by using next-generation sequencing technology. J Virol, 2011,85:11291-11299.
75. [75] Kwok H, Wu CW, Palser AL, et al. Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J Virol, 2014,88:10662-10672.
76. [76] Edwards RH, Seillier-Moiseiwitsch F, Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology, 1999,261:79-95.
77. [77] Dawson CW, Eliopoulos AG, Blake SM, et al. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology, 2000,272:204-217.
78. [78] Fielding CA, Sandvej K, Mehl AM, et al. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J Virol, 2001,75:9129-9141.
79. [79] Chan ASC, To KF, Lo KW, et al. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from Southern Chinese. Cancer Res, 2000,60:5365-5370.
80. [80] Lo KW, Chung GTY, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Sem Cancer Biol, 2012,22:79-86.
81. [81] Lung HL, Cheung AKL, Ko JMY, et al. Deciphering the molecular genetic basis of NPC through functional approaches. Sem Cancer Biol, 2012,22:87-95.
82. [82] Chan ASC, To KF, Lo KW, et al. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from Southern Chinese. Int J Cancer, 2002,102:300-303.
83. [83] Knox PG, Li QX, Rickinson AB, Young LS. In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus: cell interaction observed in nasopharyngeal carcinoma. Virology, 1996,215:40-50.
84. [84] Tsang CM, Yip YL, Lo KW, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A, 2012,109:E3473-E3482.
85. [85] Lee JH, Kim SH, Han SH, et al. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroent Hepatol, 2009,24:354-365.
86. [86] Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis show that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology, 2009,137:824-833.
87. [87] Imai S, Koizumi S, Sugiura M, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A, 1994,91:9131-9135.
88. [88] Lee HS, Chang MS, Yang HK, et al. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res, 2004, 10:1698-1705.
89. [89] Schneider BG, Gulley ML, Eagan P, et al. Loss of p16/CDKN2A tumour suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Hum Pathol, 2000,31:45-50.
90. [90] Ushiku T, Chong JM, Uozaki H, et al. p73 gene promoter methylation in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer, 2006,120:60-66.
91. [91] van Rees BP, Caspers E, zur Hausen A, et al. Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumour suppressor pathway. Am J Pathol, 2002,161:1207-1213.
92. [92] Wang K, Yuen ST, Lee SP, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet, 2014, 46:573-582.
93. [93] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 2014, 513:202-209.
94. [94] zur Hausen A, van Rees BP, van Beek J, et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol, 2004, 57:487-491.
95. [95] Corvalan A, Ding S, Koriyama C, et al. Association of a distinctive strain of Epstein-Barr virus with gastric cancer. Int J Cancer, 2006, 118:1736-1742.
96. [96] Wildeman MA, Novalic Z, Verkuijlen SA, et al. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors. Clin Cancer Res, 2012,18:5061-5070.
97. [97] Li JH, Shi W, Chia M, et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther, 2003,8:964-973.
98. [98] Taylor GS, Jia H, Harrington K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res, 2014,20:5009-5022.
99. [99] Chan KC, Hung EC, Woo JK, et al. Early detection of naso-pharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. Cancer, 2013, 119:1838-1844.